Shots:
- Skyhawk to receive $40M as upfront and is eligible to receive up to $2.2B as milestones along with royalties on sales. Vertex to get an option to exclusively license WW IP rights to candidates discovered and developed under the collaboration directed at serious diseases
- Following the exercise of its options, Vertex will be responsible for further development and commercialization
- Skyhawk will use its SkySTAR platform to discover & develop novel small molecule therapeutics that modulate RNA splicing targeting the serious disease
Click here to read full press release/ article | Ref: PRNewswire | Image: Businesswire
The post Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases first appeared on PharmaShots.
